A Phase 2 interventional study of UK-500,001 in Pulmonary Disease, Chronic Obstructive, sponsored by Pfizer. Terminated at 28 sites in 10 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2007-07-23.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
This initial proof of concept, phase II study aims to assess the safety and efficacy of UK-500,001 for the chronic maintenance treatment of adults with Chronic Obstructive Pulmonary Disease.
3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.
This study's enrollment of 324 is above the median of 72 across 2,118 interventional studies indexed under Lung Diseases.
Browse Lung Diseases studies →Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.
Of its 582 completed or terminated interventional studies of FDA-regulated products, 381 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Change from baseline in forced expiratory volume in 1 second (FEV1) compared to placebo
Change from baseline in other lung function parameters, dyspnea, quality of life compared to placebo
This study is terminated, as verified in Jul 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer